Tonix Pharma (TNXP)
11.07
-0.81 (6.82%)
Upcoming Events
Latest Headlines
Tonix Pharmaceuticals presents fibromyalgia opioid use data at medical meeting
May 28, 2026 4:31 PM - StreetInsider
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meet
May 28, 2026 4:30 PM - Globe NewsWire
Form 8-K Tonix Pharmaceuticals For: May 27
May 27, 2026 7:06 AM - SEC Filing
Tonix publishes phase 1 data for TNX-1500 transplant rejection drug
May 27, 2026 7:01 AM - StreetInsider
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
May 27, 2026 7:00 AM - Globe NewsWire
Tonix presents fibromyalgia patient data at ISPOR meeting
May 26, 2026 7:01 AM - StreetInsider
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2
May 26, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G/A Tonix Pharmaceuticals Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:30 PM - SEC Filing
Form 8-K Tonix Pharmaceuticals For: May 15
May 15, 2026 9:26 AM - SEC Filing
Form SCHEDULE 13G Tonix Pharmaceuticals Filed by: Sirenia Capital Management LP
May 15, 2026 8:06 AM - SEC Filing
Form 4 Tonix Pharmaceuticals For: May 12 Filed by: Stillwell Richard Newcomb
May 14, 2026 5:49 PM - SEC Filing
Form 4 Tonix Pharmaceuticals For: May 12 Filed by: OLUKOTUN ADEOYE Y
May 14, 2026 5:48 PM - SEC Filing
Form 4 Tonix Pharmaceuticals For: May 12 Filed by: Bell Margaret Smith
May 14, 2026 5:47 PM - SEC Filing
Form 4 Tonix Pharmaceuticals For: May 12 Filed by: Hunter James Randolph Jr
May 14, 2026 5:46 PM - SEC Filing
Form 4 Tonix Pharmaceuticals For: May 12 Filed by: Treco James
May 14, 2026 5:46 PM - SEC Filing
Form 4 Tonix Pharmaceuticals For: May 12 Filed by: GRANGE DAVID L
May 14, 2026 5:44 PM - SEC Filing
Form 4 Tonix Pharmaceuticals For: May 12 Filed by: BAGGER RICHARD H
May 14, 2026 5:43 PM - SEC Filing
Form 4 Tonix Pharmaceuticals For: May 12 Filed by: Taylor Carolyn E.
May 14, 2026 5:42 PM - SEC Filing
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
May 14, 2026 7:00 AM - Globe NewsWire
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
May 12, 2026 4:30 PM - Globe NewsWire
Form 8-K Tonix Pharmaceuticals For: May 11
May 11, 2026 5:18 PM - SEC Filing
Form 10-Q Tonix Pharmaceuticals For: Mar 31
May 11, 2026 5:16 PM - SEC Filing
Tonix Pharma (TNXP) Misses Q1 EPS by 35c
May 11, 2026 4:33 PM - StreetInsider
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
May 11, 2026 4:30 PM - Globe NewsWire
Form 8-K Tonix Pharmaceuticals For: May 07
May 7, 2026 5:21 PM - SEC Filing
Form 8-K Tonix Pharmaceuticals For: May 06
May 6, 2026 7:06 AM - SEC Filing
Tonix secures coverage for fibromyalgia drug for 35 million patients
May 6, 2026 7:01 AM - StreetInsider
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
May 6, 2026 7:00 AM - Globe NewsWire
TD Cowen Starts Tonix Pharma (TNXP) at Buy
May 4, 2026 5:30 AM - StreetInsider
Form 8-K Tonix Pharmaceuticals For: May 01
May 1, 2026 4:58 PM - SEC Filing
Form 8-K Tonix Pharmaceuticals For: Apr 29
April 29, 2026 7:05 AM - SEC Filing
Tonix plans phase 2 study of lyme disease prevention drug by 2027
April 29, 2026 7:00 AM - StreetInsider
Tonix plans Phase 2 study of Lyme disease prevention drug TNX-4800
April 29, 2026 7:00 AM - StreetInsider
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at th
April 29, 2026 7:00 AM - Globe NewsWire
Form 8-K Tonix Pharmaceuticals For: Apr 21
April 23, 2026 7:12 AM - SEC Filing
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
April 23, 2026 7:02 AM - Globe NewsWire
Tonix publishes TONMYA pharmacokinetics study in peer-reviewed journal
April 15, 2026 7:01 AM - StreetInsider
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
April 15, 2026 7:00 AM - Globe NewsWire
Form 4 Tonix Pharmaceuticals For: Mar 31 Filed by: LEDERMAN SETH
April 1, 2026 9:31 AM - SEC Filing
Form 8-K Tonix Pharmaceuticals For: Mar 30
March 31, 2026 7:06 AM - SEC Filing
Tonix presents phase 1 data for Lyme disease prevention drug TNX-4800
March 31, 2026 7:01 AM - StreetInsider
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington
March 31, 2026 7:01 AM - Globe NewsWire
Form DEF 14A Tonix Pharmaceuticals For: May 07
March 30, 2026 8:01 AM - SEC Filing
Form SCHEDULE 13G/A Tonix Pharmaceuticals Filed by: VANGUARD GROUP INC
March 27, 2026 1:32 PM - SEC Filing
Form 8-K Tonix Pharmaceuticals For: Mar 26
March 26, 2026 7:01 AM - SEC Filing
Tonix starts dosing patients in migraine drug study
March 26, 2026 7:01 AM - StreetInsider
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine
March 26, 2026 7:00 AM - Globe NewsWire
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
March 23, 2026 4:32 PM - Globe NewsWire
Form PRE 14A Tonix Pharmaceuticals For: May 07
March 20, 2026 5:13 PM - SEC Filing
Form 4 Tonix Pharmaceuticals For: Mar 18 Filed by: LEDERMAN SETH
March 18, 2026 5:04 PM - SEC Filing
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
March 18, 2026 4:58 PM - Globe NewsWire
Tonix Pharmaceuticals changes auditor to PricewaterhouseCoopers
March 18, 2026 6:12 AM - StreetInsider
Form 8-K Tonix Pharmaceuticals For: Mar 16
March 18, 2026 6:07 AM - SEC Filing
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 17, 2026 4:35 PM - Globe NewsWire
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
March 13, 2026 8:35 AM - StreetInsider
Tonix Pharma (TNXP) Misses Q4 EPS by 79c
March 13, 2026 7:52 AM - StreetInsider
Form ARS Tonix Pharmaceuticals For: Dec 31
March 13, 2026 7:17 AM - SEC Filing
Form 8-K Tonix Pharmaceuticals For: Mar 12
March 13, 2026 6:11 AM - SEC Filing
Form 10-K Tonix Pharmaceuticals For: Dec 31
March 12, 2026 5:30 PM - SEC Filing
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
March 12, 2026 5:30 PM - Globe NewsWire
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
March 10, 2026 10:22 AM - StreetInsider
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
March 10, 2026 10:21 AM - Globe NewsWire
Form 8-K Tonix Pharmaceuticals For: Mar 10
March 10, 2026 8:06 AM - SEC Filing
Tonix presents fibromyalgia drug data at medical congress
March 10, 2026 8:02 AM - StreetInsider
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia
March 10, 2026 8:01 AM - Globe NewsWire
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
March 9, 2026 4:30 PM - Globe NewsWire
Full Article List